Summary of Clarivate's Earnings Call Company Overview - **Company**: Clarivate - **Industry**: Information Services - **Business Segments**: - Intelligence Solutions (over 50% of services) - Workflow Solutions (SaaS) - Tech-Enabled Services (primarily in Intellectual Property) [3][4] Key Business Segments - **Academia and Government**: Accounts for about 50% of business; serves 99% of the world's top 400 institutions [4] - **Intellectual Property**: Represents about one-third of business; serves in-house legal departments and law firms [5] - **Life Sciences and Healthcare**: Provides solutions to top pharma and med tech companies [5] Financial Performance Highlights - **Annual Contract Value (ACV)**: Growth improved from below 1% in 2024 to nearly 2% in 2025; guidance for 2026 is 2%-3% growth [7][8] - **Organic Recurring Revenue Growth**: Expected to accelerate from 0.5% in 2024 to between 1% and 2% in 2025 [9] - **Adjusted EBITDA**: Over $1 billion reported last year; expected profit margin expansion of 200 basis points by 2026 [10] - **Free Cash Flow**: Generated $365 million last year; anticipated to grow to about $400 million this year [11] Strategic Initiatives - **Divestiture of Life Sciences Business**: Aimed at focusing on higher growth segments (A&G and IP) and improving balance sheet quality [12][13] - **Value Creation Plan**: Focus on business model optimization, enhancing sales execution, accelerating innovation, and conducting a strategic review [17][18] - **Recurring Revenue Focus**: Shift from transactional to recurring revenue, aiming for 90% recurring revenue [37][38] AI and Innovation - **AI Integration**: Significant investments in AI across products, including research assistants and workflow agents [20][21] - **Web of Science**: Launch of AI-native platform to enhance analytics and research capabilities [26] - **Efficiency Improvements**: Independent studies show significant efficiency gains from AI implementations [27] Market Dynamics - **A&G Segment**: Improvement in renewal rates and contract value; strong funding for academic research expected to continue [42][43] - **IP Segment Growth Drivers**: Anticipated growth in patent filings due to sustained AI innovation; global patents in force have shown healthy growth [48][50] Capital Allocation - **Deleveraging Focus**: Plans to use free cash flow primarily for debt repayment; potential proceeds from the LS&H sale will also support this [55][56] Future Outlook - **Success Metrics for 2026**: Improved customer engagement with AI solutions, achievement of financial objectives, and continued organic growth in ACV and recurring revenue [57]

Core Insights - Clarivate is experiencing a "positive inflection point" after meeting its full-year financial guidance for the first time since 2019, with nearly 2% organic annual contract value (ACV) growth and over $1 billion in adjusted EBITDA for 2025 [2][5][6] Financial Performance - For 2025, Clarivate reported nearly 2% organic ACV growth, improved organic recurring revenue mix to 88%, and generated over $1 billion in adjusted EBITDA along with $365 million in free cash flow [6][7] - Fourth-quarter revenue was $617 million, with full-year revenue totaling $2.455 billion, primarily influenced by inorganic changes due to divestitures [7] - Adjusted diluted EPS for the fourth quarter was $0.20, reflecting a $0.02 sequential increase, with operating cash flow of $160 million [8] AI Strategy - Clarivate is implementing an "Intelligence Amplified" strategy, focusing on AI assistants and workflow agents, with 97% of revenue derived from proprietary solutions enhanced by AI [2][3][9] - The company has launched 10 AI assistants and AI-native solutions, now utilized by over 4,000 institutions, and expects to release more than 10 additional AI solutions in the coming year [10][12] Business Segments - The Life Sciences & Healthcare (LS&H) business is under review for potential sale to enhance focus on Academia & Government (A&G) and Intellectual Property (IP) markets, although 2026 guidance assumes LS&H will be retained for the full year [4][16] - In A&G, the segment achieved 2% organic ACV growth despite funding challenges, with a shift towards a recurring revenue model [10] - The IP segment is undergoing a turnaround with new leadership and AI product launches, showing a 270 basis points year-over-year improvement in annuities revenue [11] Capital Allocation and Leverage - Clarivate's capital allocation strategy includes $225 million in share repurchases and $200 million in bond retirements, maintaining net leverage at approximately four times [14][15] - For 2026, the company aims for 2-3% organic ACV growth, margin expansion to nearly 43%, and a free cash flow target of approximately $400 million [3][17]

Financial Data and Key Metrics Changes - In Q4 2025, revenue was $617 million, bringing the full year total to $2.455 billion, with changes driven entirely by inorganic factors due to business disposals [15] - Full year net income improved by $436 million compared to the previous year, primarily due to the absence of non-cash impairment charges and lower income tax and interest expenses [15] - Adjusted diluted EPS increased by $0.02 sequentially to $0.20 [15] - Free cash flow for the full year reached $365 million, reflecting a 2% growth over the prior year [19] Business Line Data and Key Metrics Changes - The Academia and Government segment achieved 2% organic ACV growth, with 93% of revenue now from proprietary solutions [10] - The Intellectual Property business saw a 270 basis points year-over-year improvement in annuities revenue, indicating stronger execution [12] - Life Sciences & Healthcare reported significant adoption of AI solutions, with 11,000 global active users leveraging AI research assistants [12] Market Data and Key Metrics Changes - The company reported stable revenue retention rates of 93% and expects organic annual contract value growth of 2%-3% for 2026 [13][21] - The anticipated decline in revenue due to strategic disposals is expected to be approximately $100 million, with organic recurring revenue mix improving to between 88% and 90% [21][23] Company Strategy and Development Direction - The company is focusing on selling its Life Sciences & Healthcare business to enhance emphasis on the A&G and IP markets and strengthen its balance sheet [5][49] - The AI strategy is centered on leveraging proprietary data and domain expertise to enhance product offerings, with 97% of revenue derived from proprietary assets [6][42] - The company aims to maximize shareholder value through portfolio simplification and disciplined capital allocation [14] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, expecting continued improvement in key financial metrics and organic growth acceleration supported by AI innovation [14][13] - The company acknowledges market concerns regarding AI disruption but believes its proprietary business model provides a significant competitive advantage [5][6] Other Important Information - The company has initiated a process to sell its Life Sciences & Healthcare segment, which is expected to create shareholder value and allow for a more focused operational execution across A&G and IP segments [5][49] - The company plans to continue investing in product innovation while also focusing on cost efficiencies to improve capital spending [27] Q&A Session Summary Question: Monetization model for subscriptions and AI products - Management confirmed that the subscription model is evolving, with a focus on upselling AI innovations and transitioning to more subscription-based products [32][33] Question: Revenue from proprietary data and tech-enabled workflows - Management clarified that 97% of revenue comes from proprietary data, with a significant portion from information services and enterprise software [42] Question: Considerations for selling Life Sciences and Healthcare business - The decision was based on the goal of creating shareholder value and focusing on the A&G and IP segments, which have synergies [48][49] Question: Strategic synergies between IP and A&G segments - Management highlighted the benefits of shared content and technology platforms between the two segments, which can enhance innovation and operational execution [53][56] Question: Returning the IP segment to organic revenue growth - Management expressed confidence in the IP segment's turnaround, citing strong assets and a focus on innovation and execution [60][62] Question: Capital allocation priorities - Management indicated a focus on deleveraging while also considering stock buybacks, emphasizing the attractive free cash flow yield [68][70] Question: Price realization and revenue growth composition - Management noted that improvements in ACV and recurring revenue growth are primarily driven by volume rather than price increases [72][75]

Core Insights - Clarivate Plc (NYSE:CLVT) is recognized as one of the 15 Best Technology Penny Stocks to Buy, although RBC Capital has lowered its price target from $6 to $5 while maintaining a hold rating on the stock [1] Product Launch - On November 24, Clarivate announced the launch of Derwent Patent Monitor, a software designed to simplify intellectual property and research and development collaborative patent reviews [2] - The Derwent Patent Monitor utilizes proprietary data from the Derwent World Patents Index (DWPI), which contains over 67 million invention summaries created by more than 850 Clarivate experts [3] AI Integration - The new tool employs AI to conduct threat evaluations, expediting first-pass reviews (Threat Analysis) to identify significant risks for stakeholders [4] - This AI-powered tool enhances collaboration and efficiency by facilitating structured, project-based reviews, eliminating the need for emails or spreadsheets, thus keeping teams aligned and informed [5] Company Overview - Clarivate Plc is a global entity providing data, insights, analytics, and workflow solutions across various sectors, including Academia & Government, Intellectual Property, and Life Sciences & Healthcare [5]

Core Insights - Clarivate Plc has launched Derwent Patent Monitor, a new enterprise solution designed to streamline intellectual property (IP) and research and development (R&D) patent reviews, enhancing the processes of determining patentability, assessing freedom to operate (FTO), and evaluating opposition or assertion [1][2]. Group 1: Product Features - Derwent Patent Monitor utilizes proprietary data and AI technology to provide an AI-powered evaluation of potential threats, facilitating faster first-pass reviews and identifying critical risks for stakeholders [1][2]. - The software is built on data from the Derwent World Patents Index (DWPI), which includes over 67 million invention summaries created by more than 850 subject matter experts, aimed at saving time during patent reviews [2]. Group 2: Collaboration and Efficiency - The tool is purpose-built for collaboration, allowing patent teams to conduct structured, project-based reviews and receive real-time feedback, thus eliminating the need for scattered emails and spreadsheets [3]. - By enhancing alignment and information sharing among teams, Derwent Patent Monitor aims to accelerate the patent monitoring process and improve overall efficiency [3].

Financial Data and Key Metrics Changes - Q3 revenue was $623 million, essentially flat compared to the same period last year, bringing year-to-date revenue to $1.84 billion [17] - The third quarter net loss was $28 million, an improvement driven by higher foreign exchange gains and the absence of a non-cash impairment charge recorded last year [17] - Adjusted diluted EPS was flat sequentially at $0.18, with changes attributed to the divestiture of ScholarOne [17] - Free cash flow was $115 million in Q3, totaling $276 million year-to-date, driven by adjusted EBITDA and working capital [22] Business Line Data and Key Metrics Changes - The A&G segment saw a 2% ACV growth, with a subscription mix now at 93% compared to 81% last year [7][8] - The Intellectual Property segment's recurring revenue was flat year-to-date, representing a 3% improvement in organic growth compared to the full year of 2024 [9] - Life Sciences and Health segment returned to 2% ACV growth, driven by new product introductions and AI integration [11] Market Data and Key Metrics Changes - The company secured over 100 contracts for its new content subscription framework, indicating strong market demand [8] - Renewal rates in Life Sciences and Health improved to 93%, up 100 basis points year-over-year [5] - The U.S. dollar remained weaker against foreign currencies, providing a foreign exchange tailwind on revenue [20] Company Strategy and Development Direction - The company is focused on executing its value creation plan, emphasizing product and AI development to drive organic growth [6][14] - Plans to streamline the business model and market focus include exiting A&G transactional books and the Life Sciences Real World Data Resell Market [15] - The company aims to enhance its core subscription and recurring revenue mix to improve predictability, achieving an 8% improvement this year compared to last year [7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in returning the Intellectual Property segment to sustainable growth under new leadership [9][35] - The company anticipates continued acceleration in organic annual contract value and expects to raise revenue guidance by $50 million [24] - Management believes that operational efficiency and margin expansion will be achieved through the adoption of agentic AI [14] Other Important Information - The company has completed $150 million in share repurchases year-to-date and paid down $100 million in debt [5][23] - The strategic disposals are expected to lower revenue by approximately $90 million this year, with a similar impact anticipated next year [28] Q&A Session Summary Question: Insights on the patent renewal business and competitive landscape - Management noted that the patent and trademark renewal service declined by about 3% last year but is now flat year-to-date, with expectations for improvement under new leadership [35][36] Question: Updates on new innovations in the value creation plan - Management highlighted the introduction of AI-enabled products and a renewed focus on product innovation, with several new products expected to drive growth [41][42] Question: Impact of large ebook transactions on revenue and EBITDA - Management indicated that multiple large ebook transactions positively impacted revenue, with expectations for a decline in that area moving forward [47] Question: Potential of the business after strategic changes - Management expressed optimism about returning to market growth rates of 3-4% over time, citing strong fundamentals and a supportive customer base [48][49] Question: ACV acceleration and segment contributions - Management noted improvements across all segments, particularly in Life Sciences, with expectations for continued growth in the IP segment [55] Question: Trends in patents and trademarks - Management observed a gradual increase in patents in force and anticipated a recovery in volumes driven by innovation, particularly in AI [61][62] Question: Transactional revenues and their impact on guidance - Management explained that slower attrition of disposals contributed to improved revenue guidance, with a significant portion of revenue expected to decline next year [72]